Caption Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Caption Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,000,000	Closed	-$2.7M	–	1879
2025 Q3	$2.7M	Buy	+2,000,000	New	+$2.27M	0.02%	724

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Caption Management's LXRX Position: Q3 2021 in Review

Caption Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2021, closing a stake of 54,333 shares — an estimated $250K sold.

Caption Management first reported a position in LXRX in Q2 2021 and held it in 1 quarter. The position peaked at $250K in Q2 2021. 96 funds tracked by Wall St. Rank hold LXRX as of Q3 2021.

Caption Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Caption Management sold 54,333 Lexicon Pharmaceuticals shares in Q3 2021, an estimated $250K.
Caption Management first reported a position in Lexicon Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Caption Management's Lexicon Pharmaceuticals position peaked at $250K in Q2 2021.
96 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2021.

Based on Caption Management's 13F filing for Q3 2021, filed 12 Nov 2021.